{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=104", "query": { "intervention": "SC", "page": 104 }, "page_size": 10 }, "pagination": { "page": 104, "page_size": 10, "total_count": 3868, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=105&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=103&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T09:51:38.295Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07413133", "title": "A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ABBV-8736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": "2026-02-11", "completion_date": "2026-06-19", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 2, "location_summary": "Anaheim, California • Grayslake, Illinois", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07413133" }, { "nct_id": "NCT02462252", "title": "Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aplastic Anemia", "Hypoplastic Myelodysplastic Syndrome" ], "interventions": [ { "name": "BL-8040", "type": "DRUG" }, { "name": "horse anti-thymocyte globulin (hATG)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2015-10", "completion_date": "2020-11", "has_results": false, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02462252" }, { "nct_id": "NCT07082868", "title": "A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Central Nervous System Lymphoma (PCNSL)", "Primary Central Nervous System Lymphoma", "Relapsed Primary Central Nervous System Lymphoma", "Refractory Primary Central Nervous System Lymphoma", "Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma (SCNSL)" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-08-13", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07082868" }, { "nct_id": "NCT03486392", "title": "A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "JNJ-64565111 Dose Level 1", "type": "DRUG" }, { "name": "JNJ-64565111 Dose Level 2", "type": "DRUG" }, { "name": "JNJ-64565111 Dose Level 3", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 474, "start_date": "2018-03-26", "completion_date": "2019-03-08", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03486392" }, { "nct_id": "NCT06603571", "title": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "LY3841136", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 367, "start_date": "2024-09-20", "completion_date": "2026-09-14", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 48, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06603571" }, { "nct_id": "NCT01278134", "title": "A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus placebo", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 18, "location_summary": "La Jolla, California • Sacramento, California • Orlando, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01278134" }, { "nct_id": "NCT02316964", "title": "Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "natural killer cell therapy", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Sumithira Vasu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-04-21", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2020-03-09", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02316964" }, { "nct_id": "NCT07776587", "title": "Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Yoga Therapy (YT)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2027-02-01", "completion_date": "2032-04-13", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07776587" }, { "nct_id": "NCT01640171", "title": "Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Age-related Macular Degeneration", "Central Retinal Vein Occlusion", "Diabetic Macular Edema" ], "interventions": [ { "name": "Xylocaine 2% Injectable Anesthetic", "type": "PROCEDURE" }, { "name": "Proparacaine Hydrochloride 0.5% Drop", "type": "DRUG" }, { "name": "Tetravisc 0.5% Gel", "type": "DRUG" }, { "name": "Acuvail", "type": "DRUG" }, { "name": "Intra-vitreal Anti-VEGF Drug", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Retina Vitreous Associates of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2012-07", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 1, "location_summary": "Clearwater, Florida", "locations": [ { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01640171" }, { "nct_id": "NCT04115293", "title": "Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myasthenia Gravis, Generalized" ], "interventions": [ { "name": "zilucoplan (RA101495)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ra Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 174, "start_date": "2019-09-17", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-11-09T09:51:38.295Z", "location_count": 37, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115293" } ] }